Biocryst Pharmaceuticals Inc (BCRX) Com Stk USD 0.01
1.35%- This stock can be held in a
Stocks and Shares ISA
$0.44
(5.77%)$0.44
(5.77%)Company Information
About this company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS09058V1035
- Market cap$1.64bn
- Employees536
- Shares in issue207.13m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.